KYMR Relative Valuation
KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KYMR is overvalued; if below, it's undervalued.
Historical Valuation
Kymera Therapeutics Inc (KYMR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.96 is considered Overvalued compared with the five-year average of -15.38. The fair price of Kymera Therapeutics Inc (KYMR) is between 38.94 to 60.73 according to relative valuation methord. Compared to the current price of 76.69 USD , Kymera Therapeutics Inc is Overvalued By 26.29%.
Relative Value
Fair Zone
38.94-60.73
Current Price：76.69
26.29%
Overvalued
-19.50
PE
1Y
3Y
5Y
-12.06
EV/EBITDA
Kymera Therapeutics Inc. (KYMR) has a current EV/EBITDA of -12.06. The 5-year average EV/EBITDA is -13.20. The thresholds are as follows: Strongly Undervalued below -38.25, Undervalued between -38.25 and -25.72, Fairly Valued between -0.67 and -25.72, Overvalued between -0.67 and 11.85, and Strongly Overvalued above 11.85. The current Forward EV/EBITDA of -12.06 falls within the Historic Trend Line -Fairly Valued range.
-13.30
EV/EBIT
Kymera Therapeutics Inc. (KYMR) has a current EV/EBIT of -13.30. The 5-year average EV/EBIT is -9.95. The thresholds are as follows: Strongly Undervalued below -25.07, Undervalued between -25.07 and -17.51, Fairly Valued between -2.39 and -17.51, Overvalued between -2.39 and 5.16, and Strongly Overvalued above 5.16. The current Forward EV/EBIT of -13.30 falls within the Historic Trend Line -Fairly Valued range.
124.96
PS
Kymera Therapeutics Inc. (KYMR) has a current PS of 124.96. The 5-year average PS is 36.79. The thresholds are as follows: Strongly Undervalued below -7.58, Undervalued between -7.58 and 14.61, Fairly Valued between 58.98 and 14.61, Overvalued between 58.98 and 81.16, and Strongly Overvalued above 81.16. The current Forward PS of 124.96 falls within the Strongly Overvalued range.
-23.25
P/OCF
Kymera Therapeutics Inc. (KYMR) has a current P/OCF of -23.25. The 5-year average P/OCF is -27.56. The thresholds are as follows: Strongly Undervalued below -110.45, Undervalued between -110.45 and -69.00, Fairly Valued between 13.88 and -69.00, Overvalued between 13.88 and 55.33, and Strongly Overvalued above 55.33. The current Forward P/OCF of -23.25 falls within the Historic Trend Line -Fairly Valued range.
-21.46
P/FCF
Kymera Therapeutics Inc. (KYMR) has a current P/FCF of -21.46. The 5-year average P/FCF is -17.26. The thresholds are as follows: Strongly Undervalued below -45.70, Undervalued between -45.70 and -31.48, Fairly Valued between -3.04 and -31.48, Overvalued between -3.04 and 11.18, and Strongly Overvalued above 11.18. The current Forward P/FCF of -21.46 falls within the Historic Trend Line -Fairly Valued range.
Kymera Therapeutics Inc (KYMR) has a current Price-to-Book (P/B) ratio of 5.52. Compared to its 3-year average P/B ratio of 3.46 , the current P/B ratio is approximately 59.22% higher. Relative to its 5-year average P/B ratio of 4.41, the current P/B ratio is about 25.18% higher. Kymera Therapeutics Inc (KYMR) has a Forward Free Cash Flow (FCF) yield of approximately -3.95%. Compared to its 3-year average FCF yield of -9.05%, the current FCF yield is approximately -56.29% lower. Relative to its 5-year average FCF yield of -7.34% , the current FCF yield is about -46.10% lower.
5.52
P/B
Median3y
3.46
Median5y
4.41
-3.95
FCF Yield
Median3y
-9.05
Median5y
-7.34
Competitors Valuation Multiple
The average P/S ratio for KYMR's competitors is 225.08, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 124.96, which is -44.48% above the industry average. Given its robust revenue growth of -26.12%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KYMR increased by 93.71% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -1.67K to -2.97K.
The secondary factor is the P/E Change, contributed 41.84%to the performance.
Overall, the performance of KYMR in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
LIVN
LivaNova PLC
64.62USD
0.78%
AZZ
AZZ Inc
109.83USD
-0.53%
PLTK
Playtika Holding Corp
3.7USD
-6.33%
ENOV
Enovis Corp
27.69USD
-0.82%
STNE
StoneCo Ltd
14.07USD
-6.88%
FLNC
Fluence Energy Inc
20.56USD
-5.82%
TTMI
TTM Technologies Inc
70.18USD
-0.38%
ABR
Arbor Realty Trust Inc
7.69USD
-3.39%
ATS
ATS Corp
28.5USD
-2.10%
DRVN
Driven Brands Holdings Inc
14.68USD
-1.87%
Frequently Asked Questions
Is Kymera Therapeutics Inc (KYMR) currently overvalued or undervalued?
Kymera Therapeutics Inc (KYMR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 124.96 is considered Overvalued compared with the five-year average of -15.38. The fair price of Kymera Therapeutics Inc (KYMR) is between 38.94 to 60.73 according to relative valuation methord. Compared to the current price of 76.69 USD , Kymera Therapeutics Inc is Overvalued By 26.29% .
What is Kymera Therapeutics Inc (KYMR) fair value?
KYMR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Kymera Therapeutics Inc (KYMR) is between 38.94 to 60.73 according to relative valuation methord.
How does KYMR's valuation metrics compare to the industry average?
The average P/S ratio for KYMR's competitors is 225.08, providing a benchmark for relative valuation. Kymera Therapeutics Inc Corp (KYMR) exhibits a P/S ratio of 124.96, which is -44.48% above the industry average. Given its robust revenue growth of -26.12%, this premium appears unsustainable.
What is the current P/B ratio for Kymera Therapeutics Inc (KYMR) as of Jan 08 2026?
As of Jan 08 2026, Kymera Therapeutics Inc (KYMR) has a P/B ratio of 5.52. This indicates that the market values KYMR at 5.52 times its book value.
What is the current FCF Yield for Kymera Therapeutics Inc (KYMR) as of Jan 08 2026?
As of Jan 08 2026, Kymera Therapeutics Inc (KYMR) has a FCF Yield of -3.95%. This means that for every dollar of Kymera Therapeutics Inc’s market capitalization, the company generates -3.95 cents in free cash flow.
What is the current Forward P/E ratio for Kymera Therapeutics Inc (KYMR) as of Jan 08 2026?
As of Jan 08 2026, Kymera Therapeutics Inc (KYMR) has a Forward P/E ratio of -19.50. This means the market is willing to pay $-19.50 for every dollar of Kymera Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Kymera Therapeutics Inc (KYMR) as of Jan 08 2026?
As of Jan 08 2026, Kymera Therapeutics Inc (KYMR) has a Forward P/S ratio of 124.96. This means the market is valuing KYMR at $124.96 for every dollar of expected revenue over the next 12 months.